KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Free Cash Flow: 2016-2024

Historic Free Cash Flow for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$4.1 billion.

  • Moderna's Free Cash Flow rose 48.75% to -$880.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 billion, marking a year-over-year increase of 32.94%. This contributed to the annual value of -$4.1 billion for FY2024, which is 6.01% down from last year.
  • As of FY2024, Moderna's Free Cash Flow stood at -$4.1 billion, which was down 6.01% from -$3.8 billion recorded in FY2023.
  • Moderna's 5-year Free Cash Flow high stood at $13.3 billion for FY2021, and its period low was -$4.1 billion during FY2024.
  • Moreover, its 3-year median value for Free Cash Flow was -$3.8 billion (2023), whereas its average is -$1.1 billion.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 580.76% in 2021, then crashed by 183.50% in 2023.
  • Over the past 5 years, Moderna's Free Cash Flow (Yearly) stood at $2.0 billion in 2020, then skyrocketed by 580.76% to $13.3 billion in 2021, then plummeted by 65.65% to $4.6 billion in 2022, then tumbled by 183.50% to -$3.8 billion in 2023, then fell by 6.01% to -$4.1 billion in 2024.